BDNF/TRKB/P75NTR polymorphisms and their consequences on antidepressant efficacy in depressed patients

Pharmacogenomics

Volumn 16, Issue 9, 2015, Pages 997-1013

  Colle, Romain ^a   Deflesselle, Eric ^a   Martin, Séverine ^a   David, Denis J ^b   Hardy, Patrick ^a   Taranu, Adéla ^a   Falissard, Bruno ^c   Verstuyft, Céline ^d,e   Corruble, Emmanuelle ^a  

^a BICÊTRE HOSPITAL   (France)

^b INSERM U1178   (France)

^c HÔPITAL PAUL BROUSSE   (France)

^d INSERM U1184   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

antidepressant remission; antidepressant response; BDNF; major depressive disorder; major depressive episode; PNTR75; single nucleotide polymorphism; TRKB

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CITALOPRAM; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LOFEPRAMINE; METHIONINE; MIRTAZAPINE; NEUROTROPHIN RECEPTOR P75; SEROTONIN UPTAKE INHIBITOR; VALINE; VENLAFAXINE; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; MEMBRANE PROTEIN; NERVE GROWTH FACTOR RECEPTOR; NERVE PROTEIN; NGFR PROTEIN, HUMAN; PROTEIN TYROSINE KINASE; TROPOMYOSIN-RELATED KINASE-B, HUMAN;

BIPOLAR DISORDER; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; ETHNIC DIFFERENCE; EVIDENCE BASED MEDICINE; GENETIC ASSOCIATION; HAPLOTYPE; HUMAN; MAJOR DEPRESSION; MISSENSE MUTATION; PHARMACOGENETICS; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; DEPRESSIVE DISORDER; GENETIC POLYMORPHISM; GENETICS; PSYCHOLOGY; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSIVE DISORDER; HUMANS; MEMBRANE GLYCOPROTEINS; NERVE TISSUE PROTEINS; POLYMORPHISM, GENETIC; PROTEIN-TYROSINE KINASES; RECEPTORS, NERVE GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84937000611     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.15.56     Document Type: Review

References (92)

1. Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STARD: implications for clinical practice. Am. J. Psychiatry 163(1), 28-40 (2006).
2. Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 379(9820), 1045-1055 (2012).
3. David DJ, Samuels BA, Rainer Q et al. Neurogenesis-dependent and-independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 62(4), 479-493 (2009).
4. Surget A, Tanti A, Leonardo ED et al. Antidepressants recruit new neurons to improve stress response regulation. Mol. Psychiatry 16(12), 1177-1188 (2011).
5. Miller BR, Hen R. The current state of the neurogenic theory of depression and anxiety. Curr. Opin. Neurobiol. 30C, 51-58 (2015).
6. Ernst A, Frisen J. Adult neurogenesis in humans-common and unique traits in mammals. PLoS Biol. 13(1), e1002045 (2015).
7. Barde YA, Edgar D, Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J. 1(5), 549-553 (1982).
8. Pruunsild P, Kazantseva A, Aid T, Palm K, Timmusk T. Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics 90(3), 397-406 (2007).
9. Lu B. Pro-region of neurotrophins: role in synaptic modulation. Neuron 39(5), 735-738 (2003).
10. Lessmann V, Gottmann K, Malcangio M. Neurotrophin secretion: current facts and future prospects. Prog. Neurobiol. 69(5), 341-374 (2003).
11. Roux PP, Barker PA. Neurotrophin signaling through the p75 neurotrophin receptor. Prog. Neurobiol. 67(3), 203-233 (2002).
12. Castren E, Rantamaki T. The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev. Neurobiol. 70(5), 289-297 (2010).
13. Barbacid M. The Trk family of neurotrophin receptors. J. Neurobiol. 25(11), 1386-1403 (1994).
14. Calavia MG, Feito J, Lopez-Iglesias L et al. The lamellar cells in human Meissner corpuscles express TrkB. Neurosci. Lett. 468(2), 106-109 (2010).
15. Nakagawara A, Liu XG, Ikegaki N et al. Cloning and chromosomal localization of the human TRK-B tyrosine kinase receptor gene (NTRK2). Genomics 25(2), 538-546 (1995).
16. Dong C, Wong ML, Licinio J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Mol. Psychiatry 14(12), 1105-1118 (2009).
17. Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Curr. Opin. Neurobiol. 10(3), 381-391 (2000).
18. Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nat. Rev. Neurosci. 6(8), 603-614 (2005).
19. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 59(12), 1116-1127 (2006).
20. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 22(8), 3251-3261 (2002).
21. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J. Neurosci. 15(11), 7539-7547 (1995).
22. Yu H, Wang DD, Wang Y, Liu T, Lee FS, Chen ZY. Variant brain-derived neurotrophic factor Val66Met polymorphism alters vulnerability to stress and response to antidepressants. J. Neurosci. 32(12), 4092-4101 (2012).
23. Calabrese F, Molteni R, Maj PF et al. Chronic duloxetine treatment induces specific changes in the expression of BDNF transcripts and in the subcellular localization of the neurotrophin protein. Neuropsychopharmacology 32(11), 2351-2359 (2007).
24. Cooke JD, Grover LM, Spangler PR. Venlafaxine treatment stimulates expression of brain-derived neurotrophic factor protein in frontal cortex and inhibits long-term potentiation in hippocampus. Neuroscience 162(4), 1411-1419 (2009).
25. Blugeot A, Rivat C, Bouvier E et al. Vulnerability to depression: from brain neuroplasticity to identification of biomarkers. J. Neurosci. 31(36), 12889-12899 (2011).
26. Rantamaki T, Vesa L, Antila H et al. Antidepressant drugs transactivate TrkB neurotrophin receptors in the adult rodent brain independently of BDNF and monoamine transporter blockade. PLoS ONE 6(6), e20567 (2011).
27. Li Y, Luikart BW, Birnbaum S et al. TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron 59(3), 399-412 (2008).
28. Liu X, Chan CB, Qi Q et al. Optimization of a small tropomyosin-related kinase B (TrkB) agonist 7, 8-dihydroxyflavone active in mouse models of depression. J. Med. Chem. 55(19), 8524-8537 (2012).
29. Dwivedi Y, Rizavi HS, Zhang H et al. Neurotrophin receptor activation and expression in human postmortem brain: effect of suicide. Biol. Psychiatry 65(4), 319-328 (2009).
30. Kim YK, Lee HP, Won SD et al. Low plasma BDNF is associated with suicidal behavior in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 31(1), 78-85 (2007).
31. Chen B, Dowlatshahi D, Macqueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol. Psychiatry 50(4), 260-265 (2001).
32. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol. Psychiatry 64(6), 527-532 (2008).
33. Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx BW, Elzinga BM. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol. Psychiatry 19(7), 791-800 (2014).
34. Tsai SJ, Cheng CY, Yu YW, Chen TJ, Hong CJ. Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am. J. Med. Genet. B Neuropsychiatr. Genet. 123B(1), 19-22 (2003).
35. Choi MJ, Kang RH, Lim SW, Oh KS, Lee MS. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res. 1118(1), 176-182 (2006).
36. Wilkie MJ, Smith D, Reid IC et al. A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression. Pharmacogenet. Genomics 17(3), 207-215 (2007).
37. Gratacos M, Soria V, Urretavizcaya M et al. A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Pharmacogenomics J. 8(2), 101-112 (2008).
38. Lin E, Chen PS, Huang LC, Hsu SY. Association study of a brain-derived neurotrophic-factor polymorphism and short-term antidepressant response in major depressive disorders. Pharmgenomics Pers. Med. 1, 1-6 (2008).
39. Yoshida K, Higuchi H, Kamata M et al. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. J. Psychopharmacol. 21(6), 650-656 (2007).
40. Gau YT, Liou YJ, Yu YW et al. Evidence for association between genetic variants of p75 neurotrophin receptor (p75NTR) gene and antidepressant treatment response in Chinese major depressive disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B(5), 594-599 (2008).
41. Licinio J, Dong C, Wong ML. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch. Gen. Psychiatry 66(5), 488-497 (2009).
42. Alexopoulos GS, Glatt CE, Hoptman MJ et al. BDNF val66met polymorphism, white matter abnormalities and remission of geriatric depression. J. Affect. Disord. 125(1-3), 262-268 (2010).
43. Bukh JD, Bock C, Vinberg M, Werge T, Gether U, Kessing LV. No interactions between genetic polymorphisms and stressful life events on outcome of antidepressant treatment. Eur. Neuropsychopharmacol. 20(5), 327-335 (2010).
44. Domschke K, Lawford B, Laje G et al. Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. Int. J. Neuropsychopharmacol. 13(1), 93-101 (2010).
45. Kang RH, Chang HS, Wong ML et al. Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. J. Psychopharmacol. 24(12), 1755-1763 (2010).
46. Lanctot KL, Rapoport MJ, Chan F et al. Genetic predictors of response to treatment with citalopram in depression secondary to traumatic brain injury. Brain Inj. 24(7-8), 959-969 (2010).
47. Pae CU, Chiesa A, Porcelli S et al. Influence of BDNF variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. Neuropsychobiology 65(1), 1-11 (2012).
48. Zou YF, Wang Y, Liu P et al. Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients. Neuropsychobiology 61(2), 71-78 (2010).
49. Kocabas NA, Antonijevic I, Faghel C et al. Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder. Int. Clin. Psychopharmacol. 26(1), 1-10 (2011).
50. Su N, Zhang L, Fei F et al. The brain-derived neurotrophic factor is associated with alcohol dependence-related depression and antidepressant response. Brain Res. 1415, 119-126 (2011).
51. Taylor WD, Mcquoid DR, Ashley-Koch A et al. BDNF Val66Met genotype and 6-month remission rates in late-life depression. Pharmacogenomics J. 11(2), 146-154 (2011).
52. Yoshimura R, Kishi T, Suzuki A et al. The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 35(4), 1022-1025 (2011).
53. Katsuki A, Yoshimura R, Kishi T et al. Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD). CNS Spectr. 17(3), 155-163 (2012).
54. Musil R, Zill P, Seemuller F et al. No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression. Eur. Arch. Psychiatry Clin. Neurosci. 263(5), 405-412 (2013).
55. Xu G, Lin K, Rao D et al. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and the early response to antidepressant in Chinese Han population. Psychiatr. Genet. 22(4), 214-215 (2012).
56. Hennings JM, Kohli MA, Czamara D et al. Possible associations of NTRK2 polymorphisms with antidepressant treatment outcome: findings from an extended tag SNP approach. PLoS ONE 8(6), e64947 (2013).
57. Illi A, Viikki M, Poutanen O et al. No support for a role for BDNF gene polymorphisms rs11030101 and rs61888800 in major depressive disorder or antidepressant response in patients of Finnish origin. Psychiatr. Genet. 23(1), 33-35 (2013).
58. Li Z, Zhang Y, Wang Z et al. The role of BDNF, NTRK2 gene and their interaction in development of treatment-resistant depression: data from multicenter, prospective, longitudinal clinic practice. J. Psychiatr. Res. 47(1), 8-14 (2013).
59. El-Hage W, Vourc'h P, Gaillard P et al. The BDNF ValMet polymorphism is associated with escitalopram response in depressed patients. Psychopharmacology 232(3), 575-581 (2014).
60. Liu YQ, Su GB, Duan CH et al. Brainderived neurotrophic factor gene polymorphisms are associated with coronary artery diseaserelated depression and antidepressant response. Mol. Med. Rep. 10(6), 3247-3253 (2014).
61. Matsumoto Y, Fabbri C, Pellegrini S et al. Serotonin transporter gene: a new polymorphism may affect response to antidepressant treatments in major depressive disorder. Mol. Diagn. Ther. 18(5), 567-577 (2014).
62. Colle R, Gressier F, Verstuyft C et al. Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients. J. Affect. Disord. 175C, 233-240 (2015).
63. PharmGKB: Clinical Annotation Levels of Evidence. www. pharmgkb. org/page/clinAnnLevels
64. Uher R, Perroud N, Ng MY et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am. J. Psychiatry 167(5), 555-564 (2010).
65. Ising M, Lucae S, Binder EB et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch. Gen. Psychiatry 66(9), 966-975 (2009).
66. Garriock HA, Kraft JB, Shyn SI et al. A genomewide association study of citalopram response in major depressive disorder. Biol. Psychiatry 67(2), 133-138 (2010).
67. Ji Y, Biernacka JM, Hebbring S et al. Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics. Pharmacogenomics J. 13(5), 456-463 (2013).
68. GENDEP Investigators1; MARS Investigators; STARD Investigators. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am. J. Psychiatry 170(2), 207-217 (2013).
69. Egan MF, Kojima M, Callicott JH et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112(2), 257-269 (2003).
70. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol. Psychiatry 15(5), 473-500 (2010).
71. Yan T, Wang L, Kuang W et al. Brain-derived neurotrophic factor Val66Met polymorphism association with antidepressant efficacy: a systematic review and meta-analysis. Asia Pac. Psychiatry 6(3), 241-251 (2014).
72. Zou YF, Ye DQ, Feng XL, Su H, Pan FM, Liao FF. Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur. Neuropsychopharmacol. 20(8), 535-544 (2010).
73. Niitsu T, Fabbri C, Bentini F, Serretti A. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry 45, 183-194 (2013).
74. Chi MH, Chang HH, Lee SY et al. Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder. J. Affect. Disord. 126(3), 430-435 (2010).
75. Henningsson S, Borg J, Lundberg J et al. Genetic variation in brain-derived neurotrophic factor is associated with serotonin transporter but not serotonin-1A receptor availability in men. Biol. Psychiatry 66(5), 477-485 (2009).
76. Kraus C, Baldinger P, Rami-Mark C et al. Exploring the impact of BDNF Val66Met genotype on serotonin transporter and serotonin-1A receptor binding. PLoS ONE 9(9), e106810 (2014).
77. Fabbri C, Porcelli S, Serretti A. From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment. Can. J. Psychiatry 59(2), 62-75 (2014).
78. Laje G, Mcmahon FJ. Genome-wide association studies of antidepressant outcome: a brief review. Prog. Neuropsychopharmacol. Biol. Psychiatry 35(7), 1553-1557 (2011).
79. Murad MH, Montori VM, Ioannidis JP et al. How to read a systematic review and meta-analysis and apply the results to patient care: users' guides to the medical literature. JAMA 312(2), 171-179 (2014).
80. Martinowich K, Hattori D, Wu H et al. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 302(5646), 890-893 (2003).
81. Wong ML, Dong C, Flores DL et al. Clinical outcomes and genome-wide association for a brain methylation site in an antidepressant pharmacogenetics study in mexican americans. Am. J. Psychiatry 171(12), 1297-1309 (2014).
82. Hochberg Z, Feil R, Constancia M et al. Child health, developmental plasticity, and epigenetic programming. Endocr. Rev. 32(2), 159-224 (2011).
83. Weaver IC, Cervoni N, Champagne FA et al. Epigenetic programming by maternal behavior. Nat. Neurosci. 7(8), 847-854 (2004).
84. Mcgowan PO, Sasaki A, D'Alessio AC et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat. Neurosci. 12(3), 342-348 (2009).
85. Oberlander TF, Weinberg J, Papsdorf M, Grunau R, Misri S, Devlin AM. Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. Epigenetics 3(2), 97-106 (2008).
86. McCarthy MI, Abecasis GR, Cardon LR et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat. Rev. Genet. 9(5), 356-369 (2008).
87. Vacic V, McCarthy S, Malhotra D et al. Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. Nature 471(7339), 499-503 (2011).
88. Williams NM, Zaharieva I, Martin A et al. Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis. Lancet 376(9750), 1401-1408 (2010).
89. Rucker JJ, Breen G, Pinto D et al. Genome-wide association analysis of copy number variation in recurrent depressive disorder. Mol. Psychiatry 18(2), 183-189 (2013).
90. Tansey KE, Rucker JJ, Kavanagh DH et al. Copy number variants and therapeutic response to antidepressant medication in major depressive disorder. Pharmacogenomics J. 14(4), 395-399 (2014).
91. International Schizophrenia C, Purcell SM, Wray NR et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460(7256), 748-752 (2009).
92. Hirasawa R, Feil R. Genomic imprinting and human disease. Essays Biochem. 48(1), 187-200 (2010).